Diligence memo · auto-generated · as of July 2, 2026

Vitazi.AI, Inc.

Vitazi.AI, Inc. looks under-valued against its niche peers and is active on financing cadence.

SourceModeled below same-niche peers while still financing on rhythm — a potential mispricing worth a closer look.

Businessfiled

Vitazi.AI, Inc. operates in Biotechnology, based in SANTA FE.

Sub-sector tags: ai/ml.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Vitazi.AI, Inc. has raised $3.5M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $1.7M on 2022-12-16.

Most recent recorded round closed around 2025-12-31.

Valuation (modeled)modeled

Provath models Vitazi.AI, Inc. at approximately $1.1M (range $360K–$1.9M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.23× the median modeled value of Seed Biotechnology companies in 2025–2027 (99 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 9 months.

Last raise 6 mo ago; this sector typically re-raises about every 14 months.

Raising on or ahead of the sector's normal rhythm.

The last round was 2.4× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 37% of Biotechnology peers (4293 compared).

Modeled value ranks above 3% of those peers.

Closest niche peers: Carna Inc., NRX Pharmaceuticals, Inc., Vicora, Inc., MH3D, Inc., Oral Genome Corp..

Peoplefiled

11 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.